TRIAL OF ANTICOAGULATION FOR ATRIAL FIBRILLATION

房颤抗凝试验

• 批准号: 3344870
• 负责人: J P KISTLER
• 金额: $ 52.21万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-07-01 至 1990-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3344870
• 关键词: anticoagulants; atrial fibrillation; blood disorder chemotherapy; disease /disorder proneness /risk; drug administration routes; drug adverse effect; embolism; heart disorder chemotherapy; hemorrhage; human subject; human therapy evaluation; stroke; warfarin

It is widely recognized that atrial fibrillation (AF) predisposes patients to embolic stroke and systemic emboli. Although oral anticoagulant therapy has been suggested to decrease the incidence of embolic events, its benefits have not been proven and its attendent risks of hemorrhage prevent its application without confirmed benefits. The purpose of this study is to evaluate the benefits and risks of oral anticoagulant therapy in reducing embolic stroke and systemic emboli in patients with AF, without rheumatic heart disease. The benefits and risks of anticoagulation will be evaluated by a randomized, controlled trial assigning patients to treatment (anticoagulation) and no treatment groups. If treatment is beneficial, the annual incidence of embolic events should decrease from 5% in the control group to less than 1% in the treatment group. The incidence of hemorrhagic complications of the treatment and control groups will be quantitated to evaluate the risks of therapy.

人们普遍认为，心房颤动 (AF) 会使患者易感 栓塞性中风和全身性栓塞。 虽然口服抗凝治疗 有人建议减少栓塞事件的发生率， 其益处尚未得到证实，并且其伴随的出血风险可预防 其应用没有得到确认的好处。 本研究的目的是 评估口服抗凝治疗的益处和风险 减少 AF 患者的栓塞性卒中和全身性栓塞，无需 风湿性心脏病。 抗凝治疗的益处和风险 通过随机对照试验对患者进行治疗评估 （抗凝）和无治疗组。 如果治疗有效，则 栓塞事件的年发生率应从对照的 5% 下降 低于治疗组的 1%。 出血的发生率 治疗组和对照组的并发症将被量化 评估治疗的风险。